3.01

1.95% -0.06

After Hours: 2.99 -0.02 -0.66%

Vistagen Therapeutics Inc (VTGN)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Vistagen Therapeutics Inc stock is traded at $3.01, with a volume of 90,332. It is down -1.95% in the last 24 hours and down -13.75% over the past month. Vistagen Therapeutics Inc is a biotechnology firm. The company is neuroscience-focused biopharmaceutical company dedicated to pursuing a pioneering approach to the development and commercialization of groundbreaking therapies for psychiatric and neurological disorders based on deep understanding of nose-to-brain neurocircuitry.

Previous Close:

$3.07

Open:

$3.06

24h Volume:

90,332

Relative Volume:

0.81

Market Cap:

$83.06M

Revenue:

$1.04M

Net Income/Loss:

$-32.07M

P/E Ratio:

-0.4667

EPS:

-6.4491

Net Cash Flow:

$-26.12M

1W Performance:

-0.66%

1M Performance:

-13.75%

6M Performance:

-42.99%

1Y Performance:

-42.56%

1-Day Range:

$2.99

$3.13

1-Week Range:

$2.96

$3.20

52-Week Range:

$2.4501

$5.86

Vistagen Therapeutics Inc Stock (VTGN) Company Profile

Name

Vistagen Therapeutics Inc

Sector

Healthcare (1190)

Industry

Biotechnology (681)

Phone

650-577-3600

Address

343 ALLERTON AVENUE, SOUTH SAN FRANCISCO

Employee

Twitter

@vistagen

Next Earnings Date

2024-08-13

Latest SEC Filings

VTGN's Discussions on Twitter

Vistagen Therapeutics Inc Stock (VTGN) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-22-22	Downgrade	Jefferies	Buy → Hold
Jul-22-22	Downgrade	Robert W. Baird	Outperform → Neutral
Jul-22-22	Downgrade	William Blair	Outperform → Mkt Perform
May-20-21	Initiated	Robert W. Baird	Outperform
Feb-18-21	Initiated	Jefferies	Buy
Jan-04-21	Upgrade	William Blair	Mkt Perform → Outperform
Jun-27-18	Initiated	Maxim Group	Buy
Feb-08-18	Reiterated	Chardan Capital Markets	Buy
Mar-28-17	Initiated	Maxim Group	Buy

View All

Vistagen Therapeutics Inc Stock (VTGN) Latest News

Sep 24, 2024

Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - Defense World

Sep 24, 2024

Great Point Partners LLC Has $5.32 Million Stock Holdings in Vistagen Therapeutics, Inc. (NASDAQ:VTGN) - MarketBeat

Sep 24, 2024

Vistagen enrols first subject in Phase III trial of social anxiety disorder drug - Yahoo Finance

Sep 24, 2024

Sep 23, 2024

Vistagen advances phase 3 trial for social anxiety treatment - Investing.com

Sep 23, 2024

Vistagen Initiates PALISADE-4 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Yahoo Finance

Sep 23, 2024

Sep 06, 2024

All You Need to Know About VistaGen Therapeutics Rating Upgrade to Buy - Benzinga

Sep 06, 2024

All You Need to Know About VistaGen Therapeutics (VTGN) Rating Upgrade to Buy - Yahoo Finance

Sep 06, 2024

Mental Disorder Treatment Market Expected to Expand at a Steady - openPR

Sep 06, 2024

Sep 05, 2024

Companies Like Vistagen Therapeutics (NASDAQ:VTGN) Are In A Position To Invest In Growth - Yahoo Finance

Sep 05, 2024

Sep 03, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Below Fifty Day Moving Average of $3.52 - MarketBeat

Sep 03, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Pass Below 50 Day Moving Average of $3.52 - Defense World

Sep 03, 2024

Aug 30, 2024

Mental Disorder Treatment Market Detailed In New Research - openPR

Aug 30, 2024

Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com Canada

Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay - Investing.com

Aug 28, 2024

Vistagen shareholders approve board nominees and executive pay By Investing.com - Investing.com UK

Aug 28, 2024

Aug 24, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Stock Price Crosses Above 50 Day Moving Average of $3.49 - Defense World

Aug 24, 2024

Vistagen Therapeutics (NASDAQ:VTGN) Shares Cross Above 50 Day Moving Average of $3.49 - MarketBeat

Aug 24, 2024

Aug 21, 2024

The Globe and Mail - The Globe and Mail

Aug 21, 2024